cirmtuzumab-ADC-7

N/A

Report date: 2022/10/23 12:26:52

Base Information

Drug Namecirmtuzumab-ADC-7
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionInactive tyrosine-protein kinase transmembrane receptor ROR1 antagonistsWnt signalling pathway modulators
TargetsInactive tyrosine-protein kinase transmembrane receptor ROR1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesVelosbio IncUniversity Of California San Diego
China Registration ClassN/A

Develop Information

Active CompaniesVelosbio IncUniversity Of California San Diego
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A